184042-58-8

Basic information

• Product Name: 1-(2'-FLUORO)ETHYL-4-(TERT-BUTYLOXYCARBONYL)PIPERAZINE
• Synonyms: 1-(2'-FLUORO)ETHYL-4-(TERT-BUTYLOXYCARBONYL)PIPERAZINE;tert-Butyl 4-(2-fluoroethyl)piperazine-1-carboxylate;1-Piperazinecarboxylic acid,4-(2-fluoroethyl)-,1,1-dimethylethyl ester
• CAS NO: 184042-58-8
• Molecular Formula: C11H21FN2O2
• Molecular Weight: 232.297
• Mol File: 184042-58-8.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-(2'-FLUORO)ETHYL-4-(TERT-BUTYLOXYCARBONYL)PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2'-FLUORO)ETHYL-4-(TERT-BUTYLOXYCARBONYL)PIPERAZINE(184042-58-8)
• EPA Substance Registry System: 1-(2'-FLUORO)ETHYL-4-(TERT-BUTYLOXYCARBONYL)PIPERAZINE(184042-58-8)

Safety Data

• Hazardous Substances Data: 184042-58-8(Hazardous Substances Data)

Usage

Chemical structure

A piperazine ring with a 2'-fluoroethyl and tert-butyloxycarbonyl groups attached to it.

Molecular weight

Approximately 219.28 g/mol

Functional groups

Piperazine ring, 2'-fluoroethyl group, and tert-butyloxycarbonyl group

Appearance

Typically a solid or crystalline substance

Solubility

Soluble in organic solvents such as methanol, ethanol, and dimethyl sulfoxide (DMSO)

Stability

Stable under normal temperature and pressure conditions

Reactivity

Can undergo various chemical reactions, such as substitution, addition, and elimination reactions

Pharmaceutical applications

Building block in the synthesis of pharmaceutical compounds

Target disorders

Central nervous system disorders, such as depression, anxiety, and schizophrenia

Antipsychotic potential

Interaction with dopamine receptors and other neurotransmitter systems

Synthesis

Can be synthesized through various chemical reactions, such as condensation, substitution, or addition reactions

Purity

Typically characterized by techniques like high-performance liquid chromatography (HPLC) or gas chromatography-mass spectrometry (GC-MS)

Safety

Handle with care, as it may have potential hazards depending on its concentration and exposure

Storage

Store in a cool, dry place, away from direct sunlight and moisture, and in a sealed container to prevent degradation or contamination.

Upstream product

• 762-49-2 2-fluoroethyl bromide 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 762-51-6 1-fluoro-2-iodoethane 
• 383-50-6 2-fluoroethyl tosylate 

Downstream Products

• 541505-04-8 N-(2-fluoroethyl)-piperazine 

Relevant articles and documents

Carbon-11 and Fluorine-18 Radiolabeled Pyridopyrazinone Derivatives for Positron Emission Tomography (PET) Imaging of Phosphodiesterase-5 (PDE5)

The cyclic guanosine monophosphate (cGMP) specific phosphodiesterase type 5 (PDE5) plays an important role in various pathologies including pulmonary arterial hypertension and cardiomyopathy. PDE5 represents an important therapeutic and/or prognostic targ

HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS

The present application relates to novel aryl compounds with heterocyclic substituents, processes for their preparation, their use for treatment and/or prevention of diseases and their use for the preparation of medicaments for treatment and/or prevention

GLYCINE COMPOUND

[Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that a compound of the present invention or a salt thereof exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. The present invention further relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound of the present invention or a salt thereof, and an excipient.

PURINE COMPOUNDS USED AS CB2 AGONISTS

A compound of the formula (I) and pharmaceutical compositions for the treatment of pain.

PURINE COMPOUNDS

A compound of the formula: and pharmaceutical compositions for the treatment or prevention of pain.

Radiofluorinated pyrimidine-2,4,6-triones as molecular probes for noninvasive MMP-targeted imaging

Matrix metalloproteinases (MMPs) are zinc- and calcium-dependent endopeptidases. Representing a subfamily of the metzincin superfamily, MMPs are involved in the proteolytic degradation of components of the extracellular matrix. Unregulated MMP expression,

Purine Compounds

A compound of the formula: and pharmaceutical compositions for the treatment of pain.

Imidazopyridine Kinase Inhibitors

The present invention provides imidazopyridine compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.

QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER

The invention concerns quinazoline derivatives of Formula (I) wherein each of Z, m, R1, n, R3,Z2 and R14 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive or anti-proliferative agent in the containment and/or treatment of solid tumour disease.

SUBSTITUTED 3-CYANOQUINOLINES AS MEK INHIBITORS

The invention concerns quinoline derivatives of Formula (I) wherein each of Z1, m, R1, n, R3, Z2 and R14 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive or anti-proliferative agent in the containment and/or treatment of solid tumour disease.